Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 383 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR News digest – cancer blood test, gum disease and junk food... July 25, 2020 10 Ways You Can Nurture A More Sustainable Garden June 18, 2021 ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... January 20, 2023 Load more HOT NEWS New on NCI’s Websites for October 2019 Scientists find cells in centre of tumours are most likely to... FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... EMA Recommends Additional Extensions of Indications for Pembrolizumab
